Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
4,749
Cochlear Ltd News & Analysis
markets
The grass is always greener: Rethinking Australian vs global equities
stocks
Wide moat healthcare leader remains undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 40.40 | 0.44% |
| CAC 40 | 8,301.12 | 33.38 | -0.40% |
| DAX 40 | 25,968.00 | 290.11 | -1.10% |
| Dow JONES (US) | 53,115.28 | 70.62 | -0.13% |
| FTSE 100 | 10,801.98 | 22.28 | -0.21% |
| HKSE | 25,329.73 | 237.26 | -0.93% |
| NASDAQ | 26,132.60 | 238.29 | -0.90% |
| Nikkei 225 | 66,215.34 | 96.59 | -0.15% |
| NZX 50 Index | 13,786.90 | 130.40 | -0.94% |
| S&P 500 | 7,650.17 | 35.97 | -0.47% |
| S&P/ASX 200 | 9,066.70 | 41.70 | 0.46% |
| SSE Composite Index | 3,979.89 | 6.41 | -0.16% |